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 ABSTRACT 
 
TITLE OF THESIS: 
OBJECTIVE QUANTIFICATION OF DAYTIME SLEEPINESS 
 
STUDENT’S NAME: 
Amanda E. Hodges 
  
THESIS CHAIR:  
Daniel J. Whitaker  
 
 
BACKGROUND: Sleep problems affect people of all ages, race, gender, and socioeconomic 
classifications. Undiagnosed sleep disorders significantly and adversely impact a person’s level of 
academic achievement, job performance, and subsequently, socioeconomic status. Undiagnosed sleep 
disorders also negatively impact both direct and indirect costs for employers, the national government, and 
the general public. Sleepiness has significant implications on quality of life by impacting occupational 
performance, driving ability, cognition, memory, and overall health. The purpose of this study is to 
describe the prevalence of daytime sleepiness, as well as other quantitative predictors of sleep continuity 
and quality.  
 
METHODS: Population data from the CDC program in fatigue surveillance were used for this secondary 
analysis seeking to characterize sleep quality and continuity variables. Each participant underwent a 
standard nocturnal polysomnography and a standard multiple sleep latency test (MSLT) on the subsequent 
day. Frequency and chi-square tests were used to describe the sample. One-Way Analysis of Variance 
(ANOVA) was used to compare sleep related variables of groups with sleep latencies of <5 minutes, 5-10 
minutes, and >10 minutes.  Bivariate and multivariate logistic regression was used to examine the 
association of the sleep variables with sleep latency time.   
 
RESULTS: The mean (SD) sleep latency of the sample was 8.8 (4.9) minutes. Twenty-four individuals had 
≥1 SOREM, and approximately 50% of participants (n = 100) met clinical criteria for a sleep disorder. 
Individuals with shorter sleep latencies, compared to those with longer latencies reported higher levels of 
subjective sleepiness, had higher sleep efficiency percentages, and longer sleep times. The Epworth 
Sleepiness Scale, sleep efficiency percentage, total sleep time, the presence of a sleep disorder, and limb 
movement index were positively associated with a mean sleep latency of <5 minutes. 
CONCLUSIONS:  The presence of a significant percentage of sleep disorders within our study sample 
validate prior suggestions that such disorders remain unrecognized, undiagnosed, and untreated. In 
addition, our findings confirm questionnaire-based surveys that suggest a significant number of the 
population is excessively sleepy, or hypersomnolent. Therefore, the high prevalence of sleep disorders and 
the negative public health effects of daytime sleepiness demand attention. Further studies are now required 
to better quantify levels daytime sleepiness, within a population based sample, to better understand their 
impact upon morbidity and mortality. This will not only expand on our current understanding of daytime 
sleepiness, but it will also raise awareness surrounding its significance and relation to public health. 
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Chapter I 
Introduction 
The purpose of this study is to describe the distribution of daytime sleepiness in a 
representative sample of a middle-aged population. Physiologic measurements can 
objectively measure daytime sleepiness and provide valid and reliable results. Numerous 
studies have described sleepiness within in a clinical population or by using subjective 
measures, but very few large scale epidemiologic studies exist that have quantified 
daytime sleepiness within the population by means of objective measures. This study will 
describe the prevalence of daytime sleepiness, as well as other quantitative predictors of 
sleep continuity and quality.    
Prevalence of sleepiness in the population 
A large scale epidemiologic study conducted by the National Center on Sleep 
Disorder Research estimates sleep problems affect 70 million people of all ages, race, 
gender, and socioeconomic classifications. Twenty five percent of children aged 1-5 have 
sleep disorders, and more than 50% of adults age 65 or above have sleep disturbances. 
Sixty percent, or about 40 million, of the 70 million affected are chronic disorders, and 
despite the wide prevalence, approximately 95% of sleep problems are undiagnosed and 
untreated (“Wake up America,” 1993).Undiagnosed sleep disorders lead to direct and 
indirect costs for employers, the national government, the general public and the 
individual. An estimated annual amount of $15.9 billion in health care costs are related to
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sleep disorders, sleep deficiency, and excessive hypersomnolence (or daytime 
sleepiness). In 1993, the National Center on Sleep Disorder Research projected an 
increase in the public health burden approximating 100 million Americans will have 
sleep disorders by 2050 (Roth, 1995; “Wake up America,” 1993). 
The recognition of sleep disturbances, sleep deprivation, and sleepiness as a 
public health problem is a fairly new identification. It was only 1987 when U.S. Congress 
passed legislation requiring the director of the National Institute of Health to coordinate a 
plan to conduct sleep research within Public Health Services division within the 
Department of Health and Human Services. The National Commission on Sleep Disorder 
Research was created by congress in 1988 to conduct a complete analysis on the current 
state of knowledge and research within sleep disorders. The resources, personnel, 
facilities, and social programs were examined and a long-term strategy to address sleep 
related problems was developed (Roth, 1995; “Wake up America,” 1993).    
What is sleep? 
A commonly held view of sleep is that it is an interruption, or break, from the 
state of wakefulness. The concept that sleep is the direct opposite of wake dates back to 
the days of Aristotle. The necessity, cause, effect and nature of sleep have aroused 
conjecture in many; however, the reason why we must sleep remains an ever-present 
question in daily living, frequently taken for granted.  
Explicit, purposeful activity occurs in the state of wakefulness. Thus a typical 
individual may believe the only part of life to be of any significance occurs during this 
time. Despite its inescapability, sleep has been socially constructed within society as 
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undesirable and surrounded by much negativity; wakefulness has been constructed as 
superior and more attractive. A vast majority of people believe themselves to be experts 
on the subject matter of sleep; the daily, firsthand experience fools many into thinking 
they are knowledgeable and confers a false sense of understanding  (Kleitman, 1987). 
What is normal human sleep? 
Behavioral sleep is defined as, “A reversible behavioral state of perpetual 
disengagement from and unresponsiveness to the environment” (Carskadon & Dement, 
2000). Non-rapid eye movement (NREM) sleep and REM sleep are the two recurrently 
cycling sleep states that constitute normal human sleep. Each sleep state is differentiated 
on the basis of physiology. In NREM sleep, the brain is comparatively inactive in a 
mobile body, and in REM sleep is an active brain (such as in wake) in a paralyzed body. 
NREM sleep is further broken down into Stage 1, Stage 2, and Stage 3 (or slow wave 
sleep). Sleep is initiated in NREM sleep, typically stage 1, and advances to deeper sleep 
by going through stage 2 and into slow wave sleep. The first REM interval occurs about 
80-100 minutes after sleep initiation. Carskadon and Dement (2000) provide an overview 
of sleep in a healthy adult following a predictable sleep schedule: a) sleep begins in 
NREM sleep, typically in stage 1 b) the sleep cycle composed of NREM and REM sleep 
alternates cyclically every 90 minutes  c) slow wave sleep follows sleep onset and 
preponderated the first  third of the night d)REM sleep is connected to the 24 hour cycle 
of physiologic body temperature and dominates the last third of the night e) Wakefulness 
within sleep totals less than 5% of the night f) State 1 normally accounts for 2-5% of 
sleep g) Stage 2 normally accounts for 45-55% of sleep h) Stage 3 normally accounts for 
3-8% of sleep i) Stage 4 normally accounts for 10-15% of sleep j) NREM sleep is 
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normally 75-80% of sleep k) REM sleep occurs in 4-6 distinct periods normally 
accounting for 20-25% of sleep. 
In the field of sleep, books, articles and other works are typically prefaced by 
stating little is actually known and understood about sleep (Kleitman, 1987). The 
recognition of sleep as a public health concern is relatively new and has lead to an 
exponential growth in sleep research and findings in the past 25 years, but sleep research 
actually dates back to the 19
th
 century.  
History of sleep disorders medicine 
Brain waves were discovered in 1875 by Caton, and the explanation of 
differences between sleep and wake states by Hans in 1930 strengthened the idea of sleep 
as an overall state of inactivity. A commonly held view in the early part of the 20
th
 
century was that sleep materialized as a reflexive response to a diminution of cerebral 
stimulation. The human electroencephalogram illustrated sleep as high-amplitude slow 
waves and wake as faster waves of low-amplitude. The stillness and immobilization of 
the body was assumed to be in correspondence with a decrease in brain activity. A 
milestone in the history of sleep disorders medicine and research was a more 
comprehensive depiction of brain-wave patterns in 1937 by Loomis et al. They also 
originated that sleep could be continuously measured along with the ability to recognize 
the presence of sleep and/or wake at any specified time without disrupting sleep. In 1949 
Moruzzi and Magoun reasserted wake as a faster, more active state and sleep as a more 
synchronized, slower state by implanting electrodes into the brainstem reticular 
formation. They described wakefulness or EEG activation and sleep or EEG 
 
 
5 
 
synchronization as a continuum. In 1951, Starzl et al. used an animal model (cat) to show 
evidence that sensory collaterals discharged into the reticular formation, thus revealing a 
neural mechanism existed that transmitted sensory stimulation into lengthened activation 
of the brain and wakefulness.  These results confirm evidence of a reticular activating 
system researched by Bremer in the 1930s. 
In 1964, the fourth annual meeting of the Association of Psychophysiological 
Study of Sleep took place at Stanford University and began to take shape as a formal 
organization. Larry Monroe reported results from his research at the meeting in Los 
Angeles in 1967, and provided evidence that sleep scoring was highly unreliable. A great 
deal of the research during that time focused on the quantification of sleep stages as 
dependent variables in the investigation of human sleep. Homogeny of scoring sleep was 
imperative in order to move the research and clinical practices in a progressive direction. 
The development of the scoring manual required meticulous attention to detail as well as 
days of profound discussion to ensure its reliability. The product of this conference forms 
the basis for the scoring manual used in present day sleep research. At the time of 
development of the scoring manual sleep disorders medicine did not exist. The effort of 
all involved in the creation and standardization was the first agreement and venture in 
sleep disorders medicine. 
The Associated Professional Sleep Societies define sleep disorders medicine as, 
“A clinical specialty which deals with the diagnosis and treatment of patients who 
complain about disturbed nocturnal sleep, excessive daytime sleepiness or some other 
sleep related problem.” Unlike other medical specialties that deal with a primary organ 
system, sleep disorders medicine starts with a single organ; the sleeping brain and then 
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examines the impact of dysfunction of that organ on a wide array of other systems. 
Pathologies may primarily involve neuronal mechanisms or secondary effects on 
psychiatric, neurological, or medical conditions. The foremost identifiable characteristic 
of sleep disorders medicine is a full diagnostic evaluation of a sleeping patient. The broad 
scope of disorders spans a range from temporary jet lag to sudden unexplained death 
during sleep (Dement, 1990) 
 Basic mechanisms of sleep and wake 
In 1917 Von Economo discovered a disease unrecognized up to that point in 
history, which he named encephalitis lethargica. While performing autopsies on his 
deceased patients, he discovered lesions concentrated within the posterior or anterior 
hypothalamus. His research revealed that while alive, patients with lesions localized with 
the posterior hypothalamus had problems staying awake while those with lesions in the 
anterior hypothalamus had problems staying asleep (or sleeping). These observations led 
to the first hypothesis that sleep was an active neural process rather than a passive 
process occurring after withdrawal of environmental stimulus (Lavie, 1993). 
Jouvet proposed specific neurotransmitters contained within particular neuronal 
systems generate sleep and wake. Chemicals serving as neurotransmitters within the 
peripheral nervous system are present in the brain; drugs that act on these 
neurotransmitters have robust effects on wake and sleep. These neurotransmitters 
constitute molecules of different structure complexity and anatomical distribution, but 
communally, they partake in the constructing the human sleep-wake cycle.   
What promotes wake?  
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The ascending reticular activating system is essential in maintaining cortical 
activation and behavioral arousal. The visceral, somatic, and special sensory systems 
provide collateral input to the neurons of the reticular formation as well as project by a 
dorsal pathway to the basal forebrain by way of the thalamus and ventral pathway. 
Pervasive impulses are relayed to the cerebral cortex from the thalamus and basal 
forebrain. Since the time of Economo, a dissociation of cortical activation and behavioral 
arousal of wakefulness have been found in humans and animals; two parallel systems 
controlled cortical activation and behavioral arousal have been discovered. Reduced 
cortical activation without a deficiency in behavioral response to stimuli was found in 
animals with lesions of the central midbrain tegmentum. The opposite was found in 
animals with lesions in the ventral tegmentum and hypothalamus; such an animal was 
behaviorally unresponsive and sustained cortical activation. 
Activating system in the forebrain 
The forebrain can independently generate cortical activation. Both thalamic and 
extrathalamic pathways transmit the activating stimulus of the reticular formation to the 
cerebral cortex. Research, in 1970, revealed neurons positioned within the posterior 
hypothalamus and basal forebrain that project to the cortical mantel initiate the relay to 
the cortex. The extrathalamic route and relay to the cortex is adequate for widespread 
cortical activation. Hypothalamic neurons were substantiated to be of great value in 
wake, given the destruction of nerve fibers of the posterior hypothalamus decreased 
wakefulness. The reticular formation provides ascending input to the posterior 
hypothalamus and the basal forebrain which subsequently project to the cerebral cortex. 
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In the continual dearth of input from the brainstem reticular formation, the systems of the 
forebrain act autonomously as activating systems and uphold cortical activation. 
Neurochemicals of wake 
Dopamine 
Strong behavioral arousal can be generated by increasing the amount of dopamine 
in the synaptic cleft (through release). Increased concentrations of dopamine through 
inhibiting reuptake, or inactivation, or restraining enzymatic catabolism of dopamine also 
lengthen the duration of behavioral arousal. For that reason, wakefulness is decreased 
when the enzymes responsible for dopamine synthesis are inhibited. Cats experienced 
muscle rigidity and lacked behavioral response after dopamine-containing neurons in the 
substantia nigra and ventral tegmental area sustained a lesion. The dopaminergic neurons 
of these areas that project to the striatum and frontal cortex are an essential component of 
behavioral arousal. Akinesia and akinetic mutism cases often include ventral midbrain 
tegmentum or ventral posterior hypothalamus lesions in the location(s) of dopaminergic 
perikarya. Characteristics of parkinsonism include degeneration of dopaminergic neurons 
in the midbrain and dopamine depletion in the striatum. Dopamine release is greatest 
during wake, and it is highly associated with stimulating and lengthening behavioral 
arousal.   
Norepinephrine 
Norepinephrine produces prolonged vigilance associated with cortical activation. 
As with dopamine, increasing concentrations of norepinephrine through various 
mechanisms prolong arousal, and if synthesis is inhibited wakefulness is decreased. 
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Noradrenergic fibers ascend into the central midbrain tegmentum; in a cat, lesions in this 
area (of noradrenergic fibers) caused the cortical activation of wakefulness to severely 
decrease. Norepinephrine-containing neurons of the locus coeruleus and brainstem that 
project to the forebrain (and cortex) take part in an essential function of cortical 
activation. Normal enhancement and prolonged wakefulness of norepinephrine is 
demonstrated in that studies have shown cooling of the locus coeruleus produces sleep in 
a waking animal, and electrical stimulation produces arousal in a sleeping animal. During 
stressful, highly aroused, or attentive waking conditions, noradrenergic neurons of the 
locus coeruleus are the most active. During slow wave sleep, they gradually decrease rate 
of discharge until they nearly stop during REM sleep. Norepinephrine is important for 
initiating and sustaining activating processes in the thalamocortical systems. 
Acetylcholine 
Acetylcholine is an important neurotransmitter for waking. Impeding the 
breakdown of acetylcholinesterase enables acetylcholine to have extended postsynaptic 
action. This extended action prolongs cortical activation, thus improving vigilance. 
Nicotine and muscarine mimic the action of acetylcholine; they improve vigilance and 
cortical fast activity. Given the behavior of the cholinergic agonists, acetylcholine seems 
to take part in cortical activation (autonomously from waking behavior) during wake and 
REM sleep. Loss of vigilance and slowing cortical activity are effects of lesions of 
cholinergic neurons in the basal forebrain. Chemical agents that inhibit or inactivate 
cholinergic cells weaken the cortical activity and aroused states characteristic of wake 
and REM cortical activation. Increased release of acetylcholine from the thalamus during 
wake and REM sleep leads to cholinergic neurons of the pons and the mesencephalon 
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discharging at higher rates compared to slow wave sleep. Increased release of 
acetylcholine from the cortex during wake and paradoxical sleep also shows cholinergic 
neurons of the basal forebrain discharging at higher rates compared to slow wave sleep. 
Firing of pyramidal cells shifts to a tonic discharge associated with cortical fast activity 
as a result of excitation by acetylcholine. Cholinergic neurons of the brainstem and basal 
forebrain may influence transmission in the thalamus and the cortex by driving 
thalamocortical transmission and fast cortical activity during wakefulness and REM 
sleep.   
Histamine 
When administered directly onto cerebral ventricles, histamine has an arousing 
effect. Lesions of histamine-containing neurons in the tuberomammillary nuclei and 
posterior hypothalamus are associated with coma and decreased wakefulness. Posterior 
hypothalamus neurotoxic lesions result in slow wave and paradoxical sleep increases, as 
well as decreased wakefulness. Histaminergic neurons turn off during REM sleep and are 
most active during cortical activation in wakefulness. The tonic discharge in thalamic and 
cortical projections associated with waking activity is the result of histamine’s action 
(excitatory, producing depolarization) on metabotropic receptors. During wakefulness, 
histamine promotes cortical activation.  
Glutamate 
Glutamate is the main excitatory neurotransmitter, and most likely the main 
neurotransmitter of the ascending reticular activating system. Some glutamate receptor 
antagonists act as sedatives; glutamate agonists produce seizures. Cortical activation of 
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spontaneous wakefulness or midbrain reticular formation stimulation causes the most 
release of glutamate form the cerebral cortex. In general, the postsynaptic receptors 
glutamate acts on are excitatory. Reticular formation neurons in the activating system, in 
the brainstem, and in the majority of the projection neurons in the forebrain, contain 
glutamate that is vital to a responsive waking state and cortical activation.   
What promotes sleep? 
Structures in the lower brainstem are capable of initiating the ascending reticular 
activating system of the upper brainstem which is suggestive of their importance in sleep 
generation. Research shows a transaction produced total insomnia when located in the 
brainstem behind the oral pontine tegmentum. Lesions of the lower pons or medulla 
reduced or abolished slow wave sleep. Research also shows the nucleus of the solitary 
tract and the neurons of the dorsal medullary reticular formation may perhaps spawn 
sleep. The 9
th
 and 10
th 
(glossopharyngeal and vagus) cranial nerve fibers relay afferent 
input from the thoracic and abdominal viscera receptors to the solitary tract. The solitary 
tract may have an effect on limbic forebrain structures and not work exclusively through 
inhibition of the reticular activating system. 
Sleep generating systems in the forebrain 
The thalamus was discovered to be the central hub for sleep in view of the fact 
that thalamic stimuli produced behavioral and EEG confirmed sleep. However, the 
thalamus is not obligatory for cortical slow wave sleep and behavioral sleep, as it is for 
cortical spindles. In addition to the brain stem, the anterior hypothalamus, basal forebrain 
and preoptic area are also central in sleep generation. Unaided, these structures are not 
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sufficient for slow wave sleep and must therefore be accompanied by involvement of the 
cerebral cortex and basal ganglia. The sleep generating system within the forebrain 
consists of neurons of the anterior hypothalamus, basal forebrain, preoptic area, and 
orbitofrontal cortex.         
Neurochemicals of sleep 
Serotonin 
The blockade of serotonin break down augments and lengthens slow wave sleep. 
Accordingly, the inhibition of the enzyme in serotonin synthesis produces insomnia, 
reversible by immediate serotonin precursor administration. The location of the 
serotonergic neurons in nuclei of the brainstem indicates involvement in the slow wave 
sleep system of the brainstem. Partial lesions to the medullary, pontine, or midbrain raphe 
serotonin nuclei in a cat reveal the amount of sleep is proportional to the amount of 
serotonin left in the brain; a complete lesion generates insomnia. Given the results seen in 
the cat, serotonin raphe neurons appear to be fundamentally involved in the brainstem 
sleep generation system. With onset, and throughout slow wave sleep, serotonergic raphe 
neurons decreased firing and the release of serotonin during slow wave sleep decreased 
compared to wakefulness. Studies show serotonin is not involved in the maintenance of 
sleep, but instead they aid slow wave sleep onset. Results from the injection of serotonin 
into the basal forebrain showed decreases in cortical activity; this was suggestive of 
serotonin’s constricting effect of cortical activation. During wake, serotonin could prime 
the brain for slow wave sleep by acting on many various types of cells and receptors, as 
well as encouraging sleep factors to build up. 
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Adenosine 
In the brain and periphery, adenosine suppresses excitatory synaptic transmission; 
cholinergic neurons in the basal forebrain and brainstem can also be inhibited. Through 
multiple receptors it inhibits neuronal discharge and blocks nerve terminals from 
releasing neurotransmitter. The facilitation of burst discharge underlying slow wave sleep 
can occur through adenosine’s hyperpolarizing action on projection neurons of the 
thalamus and cortex. Adenosine’s action in the brain can be correlated with 
thalamocortical circuit mechanisms underlying slow wave sleep. 
Gamma-aminobutyric acid (GABA) 
GABA is crucial for initiating and maintaining sleep. By inhibiting post synaptic 
potentials, the neurons of the thalamic reticular nucleus inhibit and pace thalamocortical 
relay neurons. These neurons generating thalamocortical spindles contain GABA. The 
inhibition of the thalamus is critical for slow wave sleep and the subsequent loss of 
consciousness. Some GABAergic neurons project into the posterior hypothalamus where 
they can inhibit neurons of the activating system. In the posterior hypothalamus, the 
release of GABA in slow wave sleep is higher compared to wake and paradoxical sleep. 
In the cortex, release is also highly related to slow wave sleep. Particular GABAergic 
cells and/or receptors may be active during sleep, given GABAergic cells and receptors 
are active during wakefulness in all brain regions. Both types of receptors GABA acts on 
are generally inhibitory. In the thalamocortical system, both receptors are involved in 
decreasing membrane potential linked to spindling and slow waves. By initiating, pacing, 
and maintaining discharge mechanisms that underlie slow wave activity, and by 
 
 
14 
 
inhibiting activating systems, slow wave sleep onset and continuation in part depends on 
GABAergic transmission (Jones, 1994). 
How do we measure sleep and sleepiness?  
Analogous to hunger or thirst, sleepiness is a fundamental physiological need that 
contributes to the survival of humans. Sleepiness increases while awake and it includes 
functional impairment of concentration, drifting thoughts, blurred vision, heavy eye lids, 
sleep cravings, yawning, activity reduction, eye rubbing, head drooping and ptosis. 
Sleepiness is not able to be measured directly; it can only be described by the individual 
subjectively. The transition from complete wakefulness to evident sleep is largely 
depicted by the individual’s report of sleepiness. The effects of sleepiness, such as sleep 
latency, cognitive impairments, and reaction time, can be measured directly and 
objectively. Objective assessments of these subjective complaints use sleepiness and 
vigilance tests in attempt to explain the source of the feelings. Vigilance involves 
wakefulness, alertness, and attention, for that reason, it is not considered simply an 
opposite of sleepiness. The multidimensionality of sleepiness and vigilance require an 
amalgamation of objective and subjective tests in order to obtain the most suitable 
description of the state or condition of the patient (Mathis & Hess, 2009). 
Epworth Sleepiness Scale   
The most widely used subjective questionnaire used in clinical practice is the 
Epworth Sleepiness Scale (ESS). This test is a self-administered and consists of eight 
questions. The test measures daytime sleepiness and assesses the likelihood of falling 
asleep while in eight different situations. The test taker rates the probability of falling 
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asleep in each situation on a scale of 0-3; out of a possible 24 points, a score of 5-6 is 
considered normal for a healthy adult (Johns, 1991). The straightforward questions and 
shortness of the test has greatly contributed to its high regard within the medical field. 
The ESS has also shown test-retest reliability, and it provides valid measures of sleep 
propensity in adults (Johns, 1991; Mathis & Hess, 2009). 
Berlin Questionnaire  
The Berlin Questionnaire is a product of the Conference on Sleep in Primary Care 
held in Berlin, Germany in 1996. Pulmonary and primary care physicians came to a 
consensus on the questions and content elicited by the questionnaire. The Berlin 
Questionnaire is subjective and assesses the presence of sleep disordered breathing by 
asking questions concerning risk factors and behaviors that have been proven to predict 
the presence of sleep disordered breathing. An introductory question and four subsequent 
questions relate to snoring behavior, three questions are directed towards daytime 
sleepiness and an ensuing question focuses on sleepiness while driving, and one question 
inquires about a history of high blood pressure. Body measurements and demographic 
information, such as ethnicity, age, sex, BMI, and neck circumference are also acquired 
in the questionnaire (Netzer, Stoohs, Netzer, Clark, & Strohl, 1999). 
Additional subjective tests 
The Stanford Sleepiness Scale (SSS) is an additional subjective measure that 
assesses transient sleepiness (Mathis & Hess, 2009). The evaluation appraises symptoms 
and feelings using a self-rating Likert scale with seven degrees of severity (Johns, 1991). 
The inherent nature of the test allows for repeatability within a relatively short time 
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period. The visual analogue scale (VAS) and Karolinska Sleepiness Scale (KSS) also 
assess subjective sleepiness (Johns, 1991; Mathis & Hess, 2009). 
 Objective sleepiness scales 
Self-reports of subjective sleepiness may not be dependable or consistent with the 
physical manifestations or presentation of sleepiness as observed by others. Patients 
usually underestimate and misjudge their own level of sleepiness, as only 72% of spouses 
agreed on the likelihood of falling asleep while watching television. Wrongful testimony 
may also be divulged to preserve a job or drivers license or to obtain prescription 
stimulant drugs. For this reason, objective measures also exist in attempt to gain a more 
complete understanding of the intricate complaint and problem of sleepiness (Thorpy, 
1992). 
Quantification measures of sleep continuity and quality  
Polysomnography (PSG) is a medical diagnostic test intended to diagnose 
pathological conditions associated with sleep. The diagnostic test records and provides a 
considerable amount of activity within a range of organ systems over several hours. Sleep 
stage interpretation is achieved by obtaining concurrent documentation of 
electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), 
electrocardiogram (ECG) and respiratory recordings. The multiple recordings of the PSG 
illustrate all physiological events that occur during sleep and inform researchers or 
physicians about the individual subjects sleep architecture throughout the night. The EEG 
records electrical activity of the brain and reveals the amplitude and frequency of brain 
wave during sleep. The EOG records eye movements that are critical for scoring sleep 
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stages. The EMG measured the skeletal muscle activity, mainly of the chin. The ECG 
monitors the heart and detects arrhythmias and abnormalities. The simultaneous 
recording of the different physiological events and the novel metrics used to quantify 
sleep have been a large factor greatly contributing to the understanding and progression 
of sleep as an emerging scientific discipline (Minaritzoglou & Vagiakis, 2008).  
PSG measurements of wake and sleep stages 
Wake is characterized by alpha waves of 8-12 Hz with eyes closed and mixed 
frequencies together with beta waves of >13Hz with eyes open. The EMG shows high 
levels of activity, and the EOG shows voluntary eye movement, as if the person was 
looking around. Heartbeat and breathing are faster than in stage 1, 2, and slow wave 
sleep. Stage 1 has theta waves of 4-7.99 Hz (Figure 1 below).
 Figure 1 
 
 
18 
 
Stage 1 is characterized by a stable, tonic EMG, and patterns of slow rolling eye 
movement in the EOG. The ECG slows down slightly and becomes more regular, but 
there is no specific signal for stage 1. Breathing also slows down slightly from wake 
(Figure 2 below).  
 
Figure 2. 
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Stage 2 is distinguished by theta waves (4-7.99 Hz), but the EEG must show spindles of 
12-14Hz and k complex (sudden negative deflection followed by positive component) to 
be considered stage 2. The EMG in shows a decrease in muscle tone compared to wake, 
and the EOG shows little to no movement. Bodily functions slow down; the heartbeat and 
breathing slow and becomes more regular (Figure 3 below). 
 Figure 3. 
 
 
 
 
 
20 
 
Slow wave sleep (stage 3& 4) is characterized by delta waves of 0.5-4 Hz. The EOG may 
show some activity, possibly resembling the activity of the EEG, and the EMG shows 
little to no movement. The heartbeat and breathing are slow and regular in slow wave 
sleep (Figure 4 below). 
 Figure 4. 
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REM sleep is illustrated by theta waves of 4-7.99 Hz. Low amplitude mixed frequency 
waves often occur; alpha waves may occur at 1-2 Hz lower than in wake, and swatooth 
waves of 2-6 Hz. REM sleep characteristics are shown by darting, quick movements of 
the eyes out of phase as shown in the EOG, and muscle atonia shown in the EMG (bursts 
of muscle activity may appear). The ECG shows an irregular heartbeat, and irregular 
breathing occurs as well (Figure 5 below) (Minaritzoglou & Vagiakis, 2008). 
 Figure 5. 
Quantitative measure of daytime sleepiness 
Daytime sleepiness is objectively measured using the Multiple Sleep Latency Test 
(MSLT). The MSLT is used to establish differing degrees of sleepiness and/or to 
ascertain a diagnosis of particular sleeping disorders. It is the most frequently used 
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objective diagnostic evaluation, and it stands as the only scientifically validated 
electrophysiological measure to assess the severity of excessive sleepiness. It computes 
the functional effects of sleepiness directly by measuring the readiness of a patient to fall 
asleep as well as sleepiness at two hour intervals during the normative wakefulness 
segment of the day (Thorpy, 1992). 
The MSLT consists of four or five occasions in which sleep is suggested while the 
subject is in a dark, quiet room. Sleep onset, or latency, and specific sleep stages within 
sleep are measured by using standard electrophysiological methods (Carskadon et al., 
1986) . Sleep latency is outlined as the time between “lights out” and the first epoch of 
(sleep any stage). In all naps, the average time from lights out until the first 30-second 
epoch scored as sleep is defined as the mean sleep latency. One or more epochs of REM 
sleep within 15 minutes from the first 30-second epoch scored as sleep is defined as sleep 
onset REM. A mean sleep latency of 10-20 minutes is considered normal, a latency of 5-
10 minutes is considered borderline abnormal, and a mean sleep latency of <5 minutes is 
considered pathological sleepiness (Majer et al., 2007). Measuring and deciphering 
different sleep stages within the nap opportunities provides impertinent information 
relating to a diagnosis of narcolepsy or other disorders characterized by excessive 
somnolence (Carskadon & Dement, 1987). 
Additional objective sleepiness measures 
 The Maintenance of Wakefulness Test (MWT) is a variation of the MSLT. It is 
administered under identical conditions as the MSLT, except the patient is in a 
semireclined chair and instructed to stay awake. It is commonly used to investigate an 
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improvement in alertness following a theraputic intervention (Thorpy, 1992). The Oxford 
Sleep Resistance Test (OSLER) and the psychomotor-vigilance test (PVT) are other tests 
used to quantify sleepiness by measuring reaction time (Mathis & Hess, 2009).  
Both intrinsic and extrinsic factors can lead to varying levels of sleepiness. 
Narcolepsy, sleep apnea, RLS, and other sleep disorders are the main intrinsic etiologic 
factors associated with daytime sleepiness (Dauvilliers, 2006). Sleep deprivation 
(prolonging wakefulness) and sleep restriction (reducing sleep under the individual’s 
baseline of usual required sleep) and the most common forms of extrinsic or behavioral 
factors leading to sleepiness (Reynolds & Banks, 2010). The MSLT has shown objective 
sensitivity in sleep disorders such as sleep apnea and narcolepsy and to the effects of 
sleep deprivation, sleep restriction, sleep fragmentation, and hypersomnia (Majer et al., 
2007). These objective tests can identify daytime sleepiness as well as imply the presence 
of primary sleep disorders.    
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Chapter II 
Literature Review 
Sleep disorders 
The International Classification of Sleep Disorders (ICSD) Diagnostic and 
Coding Manual was produced by the American Academy of Sleep Medicine in alliance 
with the European Sleep Research Society, the Japanese Society of Sleep Research, and 
the Latin American Sleep Society. The ICSD classifies more than 80 official sleep 
disorders (International classification, 2005). The impact, effects, presentation of 
symptoms, and impairments of each sleep disorder are extremely diverse and unique for 
each case. Several of the disorders are rather common, but the majority of the disorders 
have low prevalence within the population. In descending order, the most common 
disorders are insomnia, sleep apnea, restless legs syndrome, and narcolepsy (Schutte-
Rodin, Broch, Buysse, Dorsey, & Sateia, 2008; "Sleep disorders," 2011 ). 
Insomnia      
Insomnia is the most common sleep disorder in the United States (Roth, Franklin, 
& Bramley, 2007). Insomnia symptoms are prevalent is 33-50% of the general adult 
population, and 10-15% are disturbed or impaired by the symptoms. Risk factors for 
insomnia include increased age, female sex, shift work, and concurrent medical, 
psychiatric, sleep and substance use disorders. Though not as common, low 
socioeconomic status and unemployment may also be considered risk factors. Research 
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suggests a positive relationship between insomnia and psychiatric disorders with an 
estimated prevalence (combined with chronic pain disorders) of 50-75% (Schutte-Rodin 
et al., 2008).    
 Insomnia is defined as the subjective experience of difficulty falling asleep, 
maintaining sleep, consolidation, or complaints of nonrestorative sleep disrupting daily 
functioning; these symptoms occur despite normative sleeping opportunities. Daytime 
impairments include trouble with attention, concentration or memory, poor performance 
in school and/ or social settings, mood disturbance, irritability, decreases in motivation 
and energy, increased probability of motor vehicle accident, and anxiety or distress over 
sleep. Physically, symptoms include fatigue, headaches, gastrointestinal problems and 
tension due to lack of sleep. A multi-parametric sleep studies and sleepiness 
quantification tests are not suggested in the customary diagnosis of insomnia, unless used 
to rule out other sleeping disorders. The Epworth Sleepiness Scale or another subjective 
sleepiness test is suggested along with a two week sleep diary and 
medical/psychiatric/medication questionnaire (Schutte-Rodin et al., 2008). A diagnosis of 
insomnia involves reported interference in daily life and anguish regarding the difficulties 
with nighttime sleep (Roth et al., 2007). 
Insomnia can present as an isolated disorder; however, one or more comorbid 
medical or psychiatric conditions can exist in conjunction with insomnia. Patients 
suffering from chronic primary insomnia display signs of excessive anxiety and dwell in 
a state of hyperarousal.  Physiologic changes that characterized hyperactivity are 
increased levels of catecholamines, increased basal metabolic rate, elevated body 
temperature, abnormal heart rate, increased level of central nervous system (CNS) 
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metabolic rate, and elevated EEG activity. The hyperarousal characteristic of insomnia 
had been hypothesized to be related to elevated activity of corticotropin-releasing factor 
(CRF) and overactive hypothalamic-pituitary-adrenal axis (HPA). The HPA is entailed in 
CRF discharge. CRF secretions act on receptors in the anterior pituitary causing the 
release of ACTH into the blood which then proceeds to instigate the productions and 
release of cortisol from the adrenal cortex. Insomnia patients have comparatively higher 
levels of adrenocorticotropic hormone (ACTH) and cortisol than do individuals without 
insomnia (Roth et al., 2007).   
Sleep apnea 
Sleep apnea is the second most common sleep disorder in the United States 
("Sleep disorders," 2011). In the general U.S. population the prevalence of sleep apnea is 
estimate to be around 9% for women and 24% for men (Gottlieb et al., 2010). A 
diagnosis of obstructive sleep apnea (OSA) does not always come near the time of onset 
of the disease. Many patients and doctors alike have trouble identifying and detecting 
symptoms (Rahaghi & Basner, 1999). Given this, the average age of onset may be hard to 
detect. In children it is often referred to as growing pains, or misdiagnosed as ADHA. 
OSA can occur at any age, but prevalence and risk increases as age increases, given the 
high prevalence rates in those > 65 years of age (Levendowski et al., 2008; Bliwise, 
2004). 
The apnea hypopnea index (AHI) is most commonly used to determine OSA. A 
multi-parametric sleep study is scored for the number of apneas (cessation in airflow for 
at least 10 seconds) and hypopneas (a reduction in airflow of a certain magnitude for at 
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least 10 seconds associated with an arousal or desaturation). These test measurements can 
reveal the frequency and severity of desaturations related to the respiratory events. There 
are currently no valid or set standards to determine the severity of the disorder. A study 
assessing daytime sleepiness using a quantitative found the severity of hypoxemia as an 
independent predictor of a higher level of daytime sleepiness (short sleep latency) (Patil, 
Schneider, Schwartz, & Smith, 2007).  
The night time symptoms of obstructive sleep apnea are frequent episodes of 
partial or complete upper airway obstruction hindering breathing. This results in repeated 
arousals and oxyhemoglobin desaturations during sleep. Other symptoms include 
insomnia and nocturia. Daytime symptoms typically include pathological 
hypersomnolence difficulties concentrating and sometimes depression (Patil et al., 2007). 
Central sleep apnea is a cessation in airflow during sleep without respiratory effort; in 
OSA there is respiratory effort during respiratory events. A great majority of the events in 
CSA are hypopneas. Despite the discrete definitions, CSA and OSA have many common 
characteristics involved in the basic mechanisms and clinical presentation (Malhotra & 
Owens, 2010). The typical patient presentation is a high BMI (obese), snoring, and 
witnessed apneas (strongest predictor of OSA). Signs of OSA include crowded 
pharyngeal airspace, abnormal positioning of the mandible, reduced circomental space, 
enlarges tongue, lateral peritonsillar narrowing, swelling in the lower extremities, 
tonsillar hyperplasia, and elevated mallampati score (Patil et al., 2007). 
Increased fat deposits around the pharynx may have a compressive effect that has 
the potential to counteract the dilator muscles action of maintaining an open airway. A 
decrease in functional residual capacity of the lungs could lead to a decrease in tracheal 
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traction which in turn would increase pharyngeal collapsibility as well. Anatomical 
mechanisms alone cannot account for collapses of the pharynx in OSA patients; 
neuromuscular factors also play a role. A genioglossal EMG showed reduced activity at 
apnea onset and increased activity with arousal when the airway reopened. A loss of 
innervations of the upper airway muscles can lead to the collapse of the pharynx. It is 
probable that a combination of both mechanical loads and impaired neuromuscular 
response to the upper airway are needed to fully explain OSA (Patil et al., 2007).   
RLS/PLMD 
Restless leg syndrome is the third most common sleep disorder in the United 
States ("Sleep disorders," 2011). Primary RLS begins in childhood or early adulthood 
(symptoms develop slowly), and onset for secondary RLS typically occurs past age 45. It 
is most commonly found in Northern Europeans and Northern Americans, with a 
prevalence of 5-15%. Primary RLS is more common in women compared to men and 
inceases with age (Bliwise et al., 2005; Ohayon & Roth, 2002; Stefansson et al., 2007). 
Periodic limb movement disorder (PLMD) is estimated to be prevalent in about 3.9% of 
the population. The prevalence is higher in women, as well as individuals 20-29 years of 
age (Ohayon & Roth, 2002). Recent studies also estimate a higher prevalence of PLMD 
in children with ADHD (Picchietti, England, Walters, Willis, & Verrico, 1998).     
The symptoms (RLS) include an inherent need to move the legs (especially in 
confined spaces such as in an airplane) as well as unpleasant sensations occurring in the 
legs (or other body parts such as the arms, belly, jaw, etc) that come about more 
frequently during the evening (Stefansson et al., 2007). Patients often complain about 
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burning, tugging, tightening, aching, and “a sensation of crawling insects inside the legs.” 
Excessive daytime sleepiness is associated RLS and PLMD due to the sleep disturbances 
it causes (Littner et al., 2004).   
Electromyography recordings from the anterior tibialis during a standard 
nocturnal polysomnography are used to record periodic limb movements (Bliwise, He, 
Ansari, & Rye, 2006). The nighttime symptoms (PLMD) are described as episodic and 
cyclic typecast limb movement occurring in sleep. Due to the unpleasant sensations in the 
legs/limbs, patients might report difficulty falling asleep or maintaining sleep. The 
diagnostic criteria for RLS is the urge to move the legs accompanied by unpleasant 
sensations in the legs, the worsening of these feeling during periods of rest, the relief of 
these sensations by activity and/or movement, and worsening of the symptoms at night. A 
measurement of four or more sequential muscle contractions that last .05-10 seconds 
separated by 5-90 seconds that are 8 µV in amplitude is typically considered PLMD. All 
other explanations for insomnia or hypersimnia must be ruled out as well for a diagnosis 
of PLMD (Hornyak, Feige, Riemann, & Voderholzer, 2006; Walters & Rye, 2009).  
RLS may be a result of dopamine dysfunction in the nigro-striatal brain areas. In 
the striatum of RLS patients, advanced brain imaging has shown a decrease in dopamine 
D2 receptor binding (Bliwise et al., 2005). Dopamine synthesis in the brain and the 
regulation of dopamine receptors require iron. Unusually low Iron and ferritin have been 
found in RLS patients, the striatum and red nucleus show reduced iron stores, and the 
severity of RLS is inversely related to the amount of nigral iron (Ekbom & Ulfberg, 
2009). Current studies have looked at the post synaptic change in neural response to 
dopamine and dopamine levels outside the cell within the central nervous system. The 
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dopaminergic abnormality has yet to be explained; however, the latter of the two is 
fundamental to many hypotheses concerning neurochemical substrate underlying RLS 
symptoms (Allen, 2004). PLM may be related to insufficient dopamine levels as well, as 
it is more common in dopamine deficient conditions compared to conditions with 
dopamine excess (Littner et al., 2004). In clinical studies, PLMD has been associated 
with other mental and physical conditions such as diabetes, arthritic diseases, 
cardiovascular diseases, anemia, iron deficits, renal failure, obstructive sleep apnea, or 
affective disorders (Ohayon & Roth, 2002). 
Narcolepsy  
Narcolepsy is the fourth most common sleep disorder ("Sleep disorders," 2011). 
The archetypal age of onset is between the ages of 15-30; however, onset in younger 
children and older adults has been described. In the United States around 5% of patients 
seen in sleep clinics are diagnosed with narcolepsy (Littner et al., 2001). Stated by The 
National Institute of Neurological Disorders and Stroke (NINDS) within the National 
Institute of Health (NIH), narcolepsy is under-detected and under-diagnosed in the United 
States ("Sleep disorders," 2011).  
It is characterized by irrepressible sleepiness and sporadic manifestations of REM 
sleep during normal waking times of the day (Littner et al., 2001). Other symptoms 
include cataplexy (sudden muscle weakness prompt by an emotional event), hypnagogic 
hallucinations (dreaming while awake), disjointed sleep, and an impermanent loss of 
muscle tone and lack of ability to execute voluntary movement at sleep onset or once 
awake (sleep paralysis). Thomas Kilduff headed a research team in the latter part of the 
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1990s that located a group of neurons in the hypothalamus, and labeled their new 
discovery hypocretin cells. Based on the anatomical and physical properties of the cells, 
they theorized the cells played a part in sleep and wake regulation. In 1999, two separate 
groups headed by Mignot and Yanagisawa discovered the pathophysiology of narcolepsy 
and neurochemical basis of the state of wake. They revealed a dysfunction or deficiency 
of hypocretin cells was correlated with the clinical symptoms of narcolepsy (Taheri, 
Zeitzer, & Mignot, 2002; Sutcliffe & De Lecea, 2002).  
In patients thought to be narcoleptic, a nocturnal multi-parametric sleep study is 
preformed to establish any coexisting sleep disorders, and followed by testing to quantify 
the level of daytime sleepiness the next day. The MSLT is sensitive and reliable within 
the context of testing sleepiness due to narcolepsy; if other potential causes of excessive 
daytime sleepiness have been ruled out by a nocturnal PSG, the results of a MSLT can 
stand as diagnostic feature. A mean MSLT sleep latency of <5 minutes and two or more 
sleep onset REM periods (SOREMPs) is characteristic of 80% of narcoleptics. A clinical 
diagnosis of narcolepsy is contingent on the two main features of cataplexy or excessive 
daytime hypersomnolence. Cataplexy is difficult to detect and diagnose; unless cataplexy 
is observed by a clinician, the MSLT quantification of sleepiness is sufficient affirmation 
for the disorder (Thorpy, 1992). 
Negative public health outcomes of sleepiness and lack of sleep  
Sleep disorders affect more than one-third of the adult population. Sufficient sleep 
is interconnected with all aspects of life and healthy functioning (Bliwise, 2008). 
Daytime sleepiness has implications in public health far beyond its prevalence. It is 
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defined as the occurrence of sleepiness during a time when the individual would typically 
be expected to be awake and functional (Thorpy, 1992). Sleep restriction is a primary 
contributor to the development of daytime sleepiness (Punjabi, Bandeen-Roche, & 
Young, 2003). Medical conditions, sleep disorders, occupational demands, domestic 
responsibilities, and social/lifestyle choices also contribute to sleepiness and sizeable 
variance in sleep duration amongst the population and within individuals (Banks, Van 
Dongen, Maislin, & Dinges, 2010). Sleepiness has significant implications on quality of 
life by impacting occupational performance, driving ability, cognition, memory, and 
overall health (Carskadon & Dement 1987; Decker, Lin, Tabassum, & Reeves, 2008; 
Littner et al., 2001; Roth et al., 2007; Thorpy, 1992;).   
Occupational effects  
The occupational effects of daytime sleepiness have the potential to make many 
innocent people victims of catastrophic events. Performance tests administered after 17-
19 hours of wakefulness show performance reductions equivalent to a blood alcohol 
concentration (BAC) of 0.05%. Tests administered around 20-25 hours of wakefulness 
show results similar to that of a BAC of 0.10% (Rajaratnam & Arendt, 2001). The melt 
down incident at the Three Mile Island plant in Pennsylvania was accredited to a human 
error of omission to correct a mechanical problem because of sleepiness (Mitler et al., 
1988). In addition to Three Mile Island, Chernobyl, Bhopal, Exxon Valdez, and the 
Estonia Ferry disasters all occurred in the early morning hours and have been partially 
attributed to fatigue, sleepiness, and subsequent error. Sleepiness within the context of 
occupational effects has also been associated to loss of work hours, loss in productivity, 
and decreased earning and promotion capability (Thorpy, 1992). Research suggests 
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workers with sleeping problems were less satisfied with their job, scored lower 
performance ratings, and missed more days (Kuppermann et al., 1995). Personnel in 
essential workforce positions, such as health care workers, pilots, commercial drivers, 
and nuclear power plant workers, are at an increased risk not only for their own safety, 
but also for the safety of others as a result of fatigue and increased errors (Decker et al., 
2008; Thorpy, 1992).  
Sleepiness and motor vehicle operation 
According to U.S. statistics, 4% of deaths in motor vehicle crashes are due to 
drowsiness, sleep, and/or fatigue. Self-reports of sleepy driving suggest a much greater 
prevalence; drowsy while driving was reported at a prevalence of 29 to 55%, accounts of 
falling asleep while driving were reported at 11-31%, and crashes due to sleepiness were 
reported at a prevalence of 4-12%. Sleepiness causes more than 50,000 vehicle crashes 
per year; second only to alcohol (Guilleminault & Brooks, 2001; MacLean, Davies, & 
Thiele, 2003). A survey of long-haul, professional truck drivers discovered 40% had 
difficulty staying vigilant on at least 20% of their drives, and another 20% reported 
dozing off (Guilleminault & Brooks, 2001). Single-vehicle crashes are suspected to occur 
due to driver lapses in attention. The distribution of crashed attributed to “falling asleep 
at the wheel” illustrate two distinct peaks, with the most pronounced positioned between 
midnight and 7am. Crashes from Israel, Texas, New York, Germany and the Netherlands 
show similar, if not exact, temporal patterns (Mitler et al., 1988).   
Cognition 
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Reduced sleep impairs cognition. Experimental restriction of sleep to five hours 
across seven nights showed immediate increases in subjective sleepiness and fatigue. 
Frequency of lapses in attention and psychomotor vigilance performance showed 
significant impairment after the second night of sleep restriction. The deficits in 
performance and mood variables showed cumulative growth in deficits across the entire 
study (Dinges et al., 1997). Sleep deprivation has toxic effects across nearly all areas of 
cognitive functioning. A meta-analysis shows simple attention and vigilance tasks were 
the two cognitive domains most affected by sleep deprivation, while complex attention 
and working memory were moderately affected. Speed and accuracy on simple attention 
tests were notably affected by one night of sleep restriction showing these deficits likely 
foreshadow further cognitive deficits and could function as admonitory signs for 
impending cognitive impairments (Lim & Dinges, 2010). 
A combination of convergent and divergent skills are merged together to form the 
complex process of decision making. With a known probability of outcomes, healthy 
humans are typically risk seeking for loses but risk avoiding for gains. That is to say, if 
two options lead to a loss, the more risky option is chosen, but if two options lead to a 
gain, the less risky option is chosen. Deficient sleep causes individuals to be less risk 
avoiding for gain and less risk seeking for losses. The effect of lack of sleep on decision 
making greatly depends on how the outcomes are portrayed (a gain or a loss). 
Nonetheless, sleep deprivation diminishes sensitivity to risk, suggesting a higher 
inclination for perilous decisions (McKenna, Dickinson, Orff, & Drummond, 2007).  
Memory 
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Sleep is important for the enhanced performing of learned tasks. Sleep is not a 
necessary factor for the learning and performance of tasks, but there is substantial 
evidence suggesting sleep can enhance performance (Siegel, 2001; Stickgold, 2005). 
Sleep contributes to the consolidation, and in particular, the augmentation of memories. 
The consolidation of memories does not depend on one particular aspect of sleep. 
Multiple sleep stages (REM, stage 2, and SWS) contribute to each type of memory 
consolidation differently. Different stages of sleep are proposed to have evolved to 
provide the most favorable brain states for the consolidation of different types of 
memory. While most processes related to sleep can also occur during wakefulness, 
experimental studies have suggested sleep dependent processing only occurs during 
sleep. When measuring sleep-dependent memory enhancement (tested by a visual texture 
discrimination test, a motor sequence test, and a motor adaptation test), study participants 
showed post-training improvement after sleeping for a night but not after a corresponding 
time awake. Results suggested the amount of time spent in certain sleep stages is 
associated with the amount of improvement during a night’s sleep. The results also, 
suggest sleep deprivation can restrain overnight improvement and enhancement of 
performance, indicating these learning and memory processes only mature through sleep 
(Stickgold, 2005). In a separate study looking at behavioral alertness and sleep 
restriction, the subjects randomized the sleep duration of less than 7 hours showed 
remarkable steady deterioration in response time across the span of days. Sleep 
chronically restricted to less than 7 hours per night also showed notable daytime 
cognitive dysfunction such as state instability and reduced working memory (Banks & 
Dinges, 2007). Sleep an important function in acquiring and performing learned tasks. 
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Sleep is crucial for most favorable functioning in learning tasks, because interferences of 
sleep in wake will affect performance (Siegel, 2001).  
Adverse health outcomes attributable to lack of sleep 
Diabetes 
Short sleep duration and incident diabetes are significantly associated. Short sleep 
time is also associated with hypertension and body weight, but when controlling for those 
variables, sleep has an independent effect on the incidence of diabetes. Insulin sensitivity 
and glucose tolerance are compromised in sleep deprivation. Increased sympathetic 
nervous system activation and decreased cerebral glucose consumption effect glucose 
tolerance. The brain utilizes nearly all non-insulin-dependent glucose; as a result of 
decreased uptake, higher concentrations circulate. Over time this higher concentration of 
glusoce could play a part in creating insulin intolerance. Also contributing to insulin 
resistance is the increased evening levels of cortisol resulting from sleep deprivation. 
Cortisol counteracts insulin inhibiting peripheral utilization of glucose; the increased load 
on the pancreas gradually compromises β-cell functioning and can lead to the 
development of type 2 diabetes. Research suggests individuals sleeping for five or less 
hours have a significantly higher risk for incident diabetes (Gangwisch et al., 2007; 
Mallon, Broman, & Hetta, 2005; Van Cauter, Splegel, Tasali, & Leproult, 2008).  
Hypertension/Cardiovascular disease 
Blood pressure and heart rate follow a daily pattern, or cycle, in which the lowest 
rates occur during sleep. Sleeping fewer hours per night increases the 24-hour blood 
pressure mean and heart rate, as well as exposes an individual to elevated level of activity 
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in the sympathetic nervous system for an extended amount of time. An increase in wake 
time exposes an individual to additional waking physical and psychosocial stressors; 
exposure to stressors, including sleep deprivation, raises blood pressure by increasing 
catecholamine synthesis. Structural adaptations, such as arterial and left ventricular 
hypertrophic remodeling, could occur as a result of shorter sleep duration and retune the 
cardiovascular system to operate at an elevated pressure equilibrium. As with diabetes, 
individuals sleeping less than 5 hours a night have an increased risk for incident 
hypertension (Gangwisch et al., 2006).   
Obesity 
Research suggests short sleep duration is a significant predictor of adult and 
childhood obesity. BMI is also significant in that for every additional hours of sleep, BMI 
was 0.35 kg/m2 lower. The majority of research suggests the association of BMI and 
sleep is stronger in younger populations, with one study finding the odds of obesity in 
children with shorter sleeping times 58% greater than those with longer sleeping times. 
Leptin and ghrelin are the two hormones necessitated in appetite regulation. Ghrelin is an 
appetite stimulant and leptin signals the brain the body has been fed, generating a feeling 
of satiety. Short sleep duration is associated with increased levels of ghrelin and 
decreased levels of leptin (Knutson, 2010). Sleep restriction is associated with increased 
hunger and appetite which in turn is correlated with a higher ghrelin to leptin ratio (Van 
Cauter et al., 2008). Total sleep time (recorded by a PSG) is inversely related to ghrelin 
levels, and leptin had been implicated as a probable intermediary in the association 
between adiposity and sleep duration. Longitudinal studies show individuals sleeping 5 or 
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fewer hours per night ultimately gain more weight (Knutson, 2010; Van Cauter et al., 
2008).  
Importance of study 
The high prevalence of sleep disorders and the negative public health effects of 
daytime sleepiness demand attention. The objective quantification of daytime sleepiness 
and detection of sleep problems within a population based sample will provide 
epidemiologic prevalence data. This will not only expand on our current understanding of 
daytime sleepiness, but it will also raise awareness surrounding its significance and 
relation to public health.   
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Chapter III 
Methods 
The Institutional Review Board of the Center for Disease Control and Prevention 
(CDC) and collaborating institutions approved this study from which these data derive. 
The U.S. Department of Health and Human Services ethical principles and guidelines 
were followed in all procedures of the study to protect human subjects during research; 
participants were over 21 years old and were required to provide written confirmed 
consent. 
Study population  
The present data were generated from a study conducted from December 2002 to 
July in 2003 as part of the CDC program in fatigue surveillance (from 1997-2002). The 
surveillance study screened 56,146 adult residents, ages 18 to 69, currently living in 
Wichita by using a random digit-dialing telephone survey. The survey captured 5,295 
individuals reporting fatigue lasting a period of time greater than or equal to one month. 
Of the identified persons with fatigue, 3,528 consented to participate in the surveillance 
study; 3,634 non-fatigued (NF) controls also participated in the study. Detailed phone 
interviews and clinical evaluations were conducted at 12, 24 and 36 month intervals, for 
the 7,162 participants. Based in the results of the surveillance study, 290 participants 
were invited to the clinical study; 227 consented to participate in the clinical study 
(Reeves et al., 2005).  
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In-hospital study 
Participants were admitted to a research unit in a Wichita hospital for two days. 
At the time of admission, all subjects were reevaluated for conditions that required 
exclusion from the study. During the two days in the Wichita research hospital 
participants provided urine and blood for standard analysis and went through a 
standardized medical history review and physical. The Diagnostic Interview Schedule for 
Axis I disorders was administered by explicitly trained and licensed psychiatric 
interviewers to detect the exclusion criteria of psychiatric conditions. The researchers 
used the Medical Outcomes Survey short form-36 (SF-36) (Ware & Sherbourne, 1992) to 
assess functional impairment, the Multidimensional Fatigue Inventory (MFI) (Smets, 
Garssen, Bonke, & De Haes, 1995) to determine fatigue severity (Decker, Tabassum, Lin, 
& Reeves, 2009).  
Objective measures of nocturnal sleep and daytime sleepiness  
Sleep studies were conducted in Wichita, Kansas in a 4-bed clinical research unit 
of Wesley Medical Center. On the first night of the study the participants were asked to 
arrive three hours prior to their regular bedtime in order for the researchers to have 
sufficient time for electrode applications and bio-calibrations. On night #1 each 
participant underwent a standard nocturnal polysomnography. The following day the 
participants had a MSLT (administered and scored according to standard guidelines as 
described in Chapter II) to measure daytime sleepiness, followed by a second night of 
standard nocturnal polysomnography on night #2. The times of “lights out” and “lights 
on” were standardized for all subjects at 10:00 pm and 7:00 am. The MSLT began at 
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11:00 am the day after night #1, and consisted for three additional naps at 1:00 pm, 3:00 
pm, and 5:00 pm. 
Standard gold cup electrodes were utilized to record electroencephalography 
(EEG), electroencephalography (EOG), and electromyography (EMG) in the following 
arrangement: central EEGs (C3- A2//C4-A1), occipital EEGs (O1-A1//O2-A2) EEGs, left 
and right monopolar EOGs, surface mentalis EMGs, and a three lead electrocardiogram. 
These signals were collected at a sampling rate of 200 Hz. Inductance plethysmography-
like belts around the chest and abdomen measured respiration, a pressure transducer with 
an attached nasal cannula measured airflow, a pulse oximeter probe was placed on the 
index finger to measure hemoglobin oxygen saturation, and EMG electrodes applied to 
the anterior tibialis muscles measured leg movement.   
A registered polysomnology technologist scored all polysomnography data; the 
technologist was blinded to the classification each participant. Using the criteria for 
scoring sleep and respiratory variables based on the Sleep Heart Health Study, all data 
was manually scored as wake, stage 1, stage 2, slow wave sleep, or rapid eye movement 
(REM) sleep in 30 second epochs (Majer et al., 2007).  
Study variables 
Body mass index (BMI) was measured during the in-hospital physical, and age 
was obtained through self-report. Subjective levels of daytime sleepiness were also 
obtained through self-report by using a questionnaire-based survey, the Epworth 
Sleepiness Scale (ESS). Standard polysomnographic techniques were employed to obtain 
sleep efficiency (percentage of time asleep after lights out), total sleep time in hours 
(TST), and percentage of each sleep stage of total sleep (S1% of TST, S2% of TST, S3% 
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of TST, S4%of TST REM% of TST). The Respiratory Disturbance Index (RDI) is the 
total number of abnormal respiratory events divided by the total sleep time. The Limb 
movement Index (Lm Index) is the total number of limb movements, measured by PSG 
recording, divided by the total sleep time. The RDI and Lm Index were calculated prior 
to data entry. Mean sleep latency was obtained through the MSLT; it is calculated by 
averaging the time it took and individual to fall asleep in all 4 20-minute nap 
opportunities. A sleep onset REM period (SOREMP) (if it occurred) was detected 
through PSG measurements during the MSLT. The mean sleep latency and number of 
SOREMPs were also calculated prior to data entry. The recommendations for interpreting 
the MSLT made by Richardson et al. (1978) were used to recode the continuous variable 
(mean sleep latency) into a categorical variable with three levels: mean sleep latency of 
<5 minutes., mean sleep latency of 5-10 minutes., and mean sleep latency of >10 
minutes.    
Statistical analysis 
 PASW Statistics 18 was used for data management and statistical analysis 
purposes. Participants were separated into three groups based on MSLT mean sleep 
latency. Chi-square tests were used to examine differences for categorical variables. One-
Way Analysis of Variance (ANOVA) was used to compare means for continuous 
descriptive variables. Bivariate and multivariate logistic regression analyses were used to 
test the association of each of the sleep variables with short and long sleep latency time, 
i.e. >10 minutes vs. <5 minutes. Logistic regression was also used to test the association 
of each of the sleep variables with ≥1 SOREM. 
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Chapter IV 
Results 
Sample Characteristics 
The sample size for each variable used in the analysis is based on the consent of 
participants to provide specific data from the Wichita in-hospital study and clinical 
evaluation. Table 1 provides demographic information for the study sample (n=227). The 
majority of the sample were white females with a mean age of 50.2 (SD=9.0) and an 
average body mass index (BMI) of 28.7 (SD=4.8).  
Table 1. Demographic Characteristics of Study Sample 
Variable N (%) 
Sex           
        Female  186  81.9  
        Male  41  18.1  
Race    
        White  214  94.3  
        Black 8 3.5  
        Asian  1  .4  
        AM Indian/Alaskan 
         native  
1  .4  
        Multi  2  .9  
 N  Mean (SD)  
Age  227  50.2(9.0)  
BMI  227  28.7(4.8) 
  
The mean MSLT sleep latency of the four naps for the sample was 8.8 minutes 
(SD=4.9 minutes); 57 individuals (26.8%) had a sleep latency <5 minutes, 79 individuals 
(37.1%) had a sleep latency between 5-10 minutes, and 77 individuals (36.2%) had a 
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sleep latency > 10 minutes. Table 2 provides demographic information for these sleep 
latency groups. There were no significant differences between sex, BMI, or age between 
groups. 
Table 2. Demographic Characteristics of Sample by MSLT Mean Sleep Latency  
Variable  Mean sleep latency  
<5 min. (n=57)  
Mean sleep latency  
5-10 min. (n=79)  
Mean sleep 
latency >10 
min.(n=77)  
p 
value 
Sex (%)    .28  
     Male
a
   26.3(n=10) 47.4(n=18) 26.3(n=10)  
     Female
b
  26.9(n=47) 34.9(n=61) 38.3 (n=67)  
     
 Mean (SD) Mean (SD) Mean (SD)  
BMI  29.2(4.6) 29.1(5.1) 28.3(4.7) .53  
Age  49.9 (9.1) 50.8 (7.8) 50.6 (9.6) .82  
     
a. (n=38) 
b. (n=175) 
Sleep quality and continuity 
A mean MSLT sleep latency of 10-20 minutes is considered normal, a latency of 
5-10 minutes is considered borderline abnormal, and a sleep latency of <5 minutes is 
considered pathological sleepiness (Majer et al., 2007). Table 3 shows results from 
ANOVAs comparing the three sleep latency groups on physiologic measures from the 
night prior to the MSLT and the Epworth Sleepiness Scale (ESS). Individuals with a 
sleep latency of < 5 minutes reported significantly higher levels of subjective daytime 
sleepiness on the self-administered ESS, than individuals with a sleep latency of > 10 
minutes (p=.001). Sleep efficiency percent and total sleep time (TST) were also 
significantly different between the three groups. Individuals with a sleep latency of <5 
minutes had significantly better sleep efficiency than those with a sleep latency of > 10 
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minutes (p=.001). Total sleep time of participants with a sleep latency of < 5 minutes and 
5-10 minutes were significantly lower than participants with a latency of > 10 minutes 
(p<.0001). There were no significant differences between groups in sleep stage 
percentage of total sleep time (S1-4% of TST, REM % of TST), respiratory disturbance 
index (RDI), or limb movement index (Lm Index). 
Table 3. Central Tendency of Sleep Architecture Data by MSLT Mean Sleep Latency  
Variable Sleep Latency 
<5 min. 
(n=57) 
Sleep Latency 
5-10 min. 
(n=79) 
Sleep Latency 
>10 min. 
(n=77) 
df F p 
value  
 M (SD) M (SD) M (SD)    
ESS Score  11 (5)
a
 9 (5)
ab
 8 (5)
b
 (2,210) 6.72 .001  
Sleep 
Efficiency %  
90.0 (7.5)
a
 86.4 (8.4)
ab
 82.5 (14.8)
b
 (2,209) 7.88 .001  
TST 
(minutes)  
409.4 (44.3)
a
 385.8 (47.7)
a
 357.9 (77.4) 
b
 (2,209) 12.50 <.0001  
S1% of TST  8.3 (4.5) 8.3 (3.9) 8.9 (5.7) (2,206) .44 .645  
S2% of TST  51.7 (9.2) 51.8 (9.9) 51.8 (9.6) (2,206) .001 .999  
S3% of TST  11.9 (6.5) 11.1 (5.1) 12.8 (6.2) (2,206) 1.42 .243  
S4% of TST  5.9 (5.1) 5.5 (5.7) 5.9 (6.5) (2,206) .10 .907  
REM% of 
TST  
22.2 (6.5) 23.3 (6.7) 20.7 (7.1) (2,206) 2.99 .053  
RDI  5.7 (9.5) 5.0 (7.3) 5.8 (9.7) (2,209) .18 .109  
Lm Index  9.8 (13.9) 6.7 (13.2) 5.2 (9.8) (2,204) 2.24 .109  
Means with different subscripts are significantly different based on Tukey’s test at p < 
.05; ESS, Epworth Sleepiness Scale; TST, total sleep time; S1% TST, stage 1 percentage 
of total sleep time; S2% TST, stage 2 percentage of total sleep time; S3% TST, stage 3 
percentage of total sleep time; S4% TST, stage 4 percentage of total sleep time, REM% 
of TST, REM percentage of total sleep time; RDI, respiratory disturbance index; Lm 
Index, limb movement index  
Prevalence of sleep onset REM and previously unidentified sleep disorders      
The presence of ≥1 SOREMP during the MSLT is suggestive of sleep restriction, 
sleep deprivation, or a sleep disorder, and is considered abnormal.  As Table 4 illustrates, 
a total of 24 individuals had ≥1 SOREMP. A total of 46.9% (n=100) of the study sample 
 
 
46 
 
had unrecognized sleep disorders; 24.4% (n=52) had obstructive sleep apnea, 16.4% 
(n=35) had periodic limb movements disorder (PLMD), and 2.3% (n=5) had narcolepsy. 
The presence of ≥1 SOREMP was significantly different between the three sleep latency 
groups (p<.0001). The presence of a sleep disorder was not significant. 
Table 4. Prevalence of SOREMP and Primary Sleep Disorders by MSLT Mean Sleep 
Latency   
Variable  N  Sleep Latency 
<5 min. 
(n=57) 
Sleep Latency 
5-10 min. 
(n=79) 
Sleep Latency 
>10 min. 
(n=77) 
p 
value  
# of Sleep Onset REM       
0  189  42  70  77   
1  18  10  8  0   
2  2  2  0  0   
3  4  3  1  0   
% with ≥1 SOREMP  24 26.3% 11.4% 0% <.0001 
      
Primary Sleep 
Disorders  
     
OSA  52 14  21  17   
PLMs  35 14  11  10   
Narcolepsy 5 4  1  0   
IH  2 2  0  0   
ISS 1 0  0  1   
 Insomnia  1 0  0  1   
DSPS  2 0  0  2   
UARS 1 0  0  1   
CSA 1 0  1  0   
% with Primary Sleep 
Disorder 
100 
(%)  
34 (59.6%) 34 (43%) 32 (41.6%) .079 
Note: OSA, obstructive sleep apnea; PLMs, periodic limb movements; IH, idiopathic 
hypersomnia; ISS, insufficient sleep syndrome; DSPS, delayed sleep phase syndrome; 
UARS, upper airway resistance syndrome; CSA, central sleep apnea  
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Predictors of mean sleep latency 
 The results of bivariate analysis of the association between each of the examined 
independent sleep variables and the mean sleep latency are shown in Table 5. The 
magnitude and direction of the association between the independent variables and the 
outcome are quantified using the odds ratio from the logistic regression models. The 
Epworth Sleepiness Scale, sleep efficiency percentage, total sleep time, and the presence 
of a sleep disorder were positively associated with a mean sleep latency of <5 minutes. 
Individuals with an ESS score of 11 or higher were significantly more likely to have a 
sleep latency of <5 minutes. Individuals with a sleep efficiency percentage of over 86%, 
TST of 6 or more hours, and the presence of a primary sleep disorder were also more 
likely to have a sleep latency of <5 minutes. RDI, specific sleep stage percentages of total 
sleep time, and Lm Index were not significantly associated with a mean sleep latency of 
<5 minutes.  
Table 5. Associations of Sleep Related Variables to Mean Sleep Latency of <5 minutes  
Variable Threshold Odds Ratio 95% CI P value 
ESS Score <11 versus ≥11 3.162 (1.518-6.584) .0012 
Sleep Efficiency % ≤86% versus >86% 3.558 (1.631-7.758) .001 
TST (hours) <6h versus ≥6h 5.064 (1.926-13.314) .001 
S1% of TST 1% increase .977 (.912-1.046) .499 
S2% of TST 1% increase .999 (.963-1.037) .970 
S3% of TST 1% increase .979 (.926-1.035) .448 
S4% of TST 1% increase .999 (.942-1.059) .979 
REM% of TST 1% increase 1.034 (.982-1.089) .206 
RDI <5 versus ≥5 1.152 (.552-2.407) .706 
Lm Index <5 versus ≥5 1.611 (.751-3.457) .221 
Has primary Sleep 
Disorder 
No versus yes 2.079 (1.036-4.172) .040 
 
Multivariate logistic regression was used to determine the associations of each of the 
variables in the bivariate regression while controlling for the other covariates. Table 6 
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shows the results of the multivariate logistic regression; specific sleep stage percentages 
of total sleep time were excluded from the regression model due to multicollinearity with 
TST. The ESS was the only variable that remained significantly associated with a sleep 
latency of <5 minutes while adjusting for the other sleep variables. An EES score of 11 or 
higher was positively associated with a mean sleep latency of <5 minutes. Sleep 
efficiency percentage, TST, Lm Index, and the presence of a primary sleep disorder were 
no longer significantly associated with a sleep latency time of <5 minutes when adjusting 
for the other sleep variables.   
Table 6. Multivariate Analysis Predicting a Mean Sleep Latency of <5 minutes 
Variable  Threshold Odds Ratio  95% CI  P value  
ESS Score  <11 versus ≥11  3.450  (1.534-7.757)  .003  
Sleep Efficiency  ≤86% versus >86%  1.493  (.433-5.145)  .525  
TST (hours)  <6h versus ≥6h  3.755  (.856-16.482)  .080  
Lm Index  <5 versus ≥5  1.345  (.514-3.515)  .546  
RDI  <5 versus ≥5  .593  (.207-1.702)  .331  
Primary Sleep 
Disorder  
No versus yes  2.122  (.790-5.701)  .136  
 
Predictors of SOREMP 
The results of bivariate analysis of the association between each of the examined 
independent sleep variables and the SOREMP are shown in Table 7. The magnitude and 
direction of the association between the independent variables and the outcome are 
quantified using the odds ratio from the logistic regression models. Sleep efficiency 
percentage, S4% of TST, and REM% of TST were positively associated with 1 or more 
SOREMP. Individuals with a sleep efficiency percentage of over 86% are more likely to 
have 1 or more SOREMP, compared to those with a sleep efficiency percentage of ≤ 
86%. A 1% increase in S4% of TST increased the odds by 9% and a 1% increase in 
 
 
49 
 
REM% of TST increased the odds of 1 or more SOREMP by 7%. S1% of TST and S2% 
of TST showed a protective effect, or negative association with SOREMP. A 1% increase 
in S1% of TST decreased the odds of SOREMP by 16% and a 1% increase in S2% of 
TST decreased the odds by 6%. 
Table 7. Associations of Sleep Related Variables to ≥1 SOREMP 
Variable  Threshold Odds Ratio  95% CI  P value  
ESS Score  <11 versus ≥11  1.908  (.812-4.484)  .139  
Sleep Efficiency %  ≤86% versus >86%  5.299  (1.528-18.370)  .009  
TST (hours)  <6h versus ≥6h  3.854  (.873-17.005)  .075  
S1% of TST  1% increase  .841  (.728-.971)  .018  
S2% of TST  1% increase  .938  (.893-.984)  .009  
S3% of TST  1% increase  1.052  (.979-1.131)  .165  
S4% of TST  1% increase  1.087  (1.015-1.164)  .017  
REM% of TST  1% increase  1.075  (1.002-1.153)  .043  
RDI  <5 versus ≥5  .878  (.346-2.231)  .785  
Lm Index  <5 versus ≥5  .334  (.096-1.166)  .086  
Has primary Sleep 
Disorder  
No versus yes  1.386  (.591-3.249)  .453  
 
Multivariate logistic regression was used to determine the associations of each of the 
variables in the bivariate regression with the outcome variable of 1 or more SOREMP 
while controlling for the other covariates. Table 8 shows the results of the multivariate 
logistic regression. None of the variables significantly associated with 1 or more 
SOREMP in the bivariate analysis remained significant when adjusting for the other sleep 
related variables. The presence of a primary sleep disorder became significant while 
controlling for other covariates; individuals with a sleep disorder were more likely to 
have 1 or more SOREMP compared those without a primary sleep disorder. Lm Index 
also became significant; however, it was negatively associated with the outcome variable. 
A Lm Index of ≥5 showed a protective effect by decreasing the odds of 1 or more 
SOREMP by 81% when adjusting for the other sleep variables. 
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Table 8. Multivariate Analysis Predicting ≥1 SOREMP 
Variable  Threshold Odds Ratio  95% CI  P value  
ESS Score  <11 versus ≥11  1.745  (.706-4.313)  .227  
Sleep Efficiency  ≤86% versus >86%  5.027  (.722-34.997)  .103  
TST (hours)  <6h versus ≥6h  .950  (.094-9.554)  .965  
Lm Index  <5 versus ≥5  .190  (.046-.786)  .022  
RDI  <5 versus ≥5  .473  (.120-1.596)  .210  
Primary Sleep 
Disorder  
No versus yes  3.478  (1.023-11.821)  .046  
 
    
    
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Chapter V 
Discussion 
 
In our society sleep is often the first and most dispensable commodity. There are 
many costs associated with sleep deprivation and sleep restriction. Although these are not 
the sole factors contributing to daytime sleepiness, they do appear to account for a great 
portion of it (Ohayon, 2008). The prevalence of excessive daytime sleepiness is estimated 
to be between 12-15% within the general population. The pervasiveness of daytime 
sleepiness notably contribute to the public health burden of motor vehicle crashes, 
decreased occupational performance, cardiovascular events, cognition and memory 
impairments, and all-cause mortality. Predisposing factors include voluntary sleep 
restriction, sleep deprivation, and sleep fragmentation due to sleep disorders (Lim & 
Dinges 2010; Punjabi et al., 2003; Siegel, 2001; Stickgold, 2005).  
Daytime sleepiness is typically defined as the occurrence of sleepiness during a 
time when the individual would typically be expected to be awake and functional 
(Thorpy, 1992). Sleepiness is a complaint, thus it is only able to be subjectively described 
by the individual (Mathis & Hess, 2009). Sleepiness is complex and the difficulty in 
defining and measuring certain features is well known (Bliwise, 2001; Kim & Young, 
2005). A standardized operational definition of daytime sleepiness is nonexistent, and 
very few subjective surveys have used parallel definitions (Ohayon, 2008). The effects of 
sleepiness, such as sleep latency, cognitive impairments, and reaction time, can be 
measured directly and objectively. Objective assessments of these subjective complaints
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use sleepiness and vigilance tests in attempt to explain the source of the feelings (Mathis 
& Hess, 2009). Various studies have been conducted investigating the relationship 
between subjective and objective measures; the findings are inconsistent, ranging from 
minimal to moderate associations (Benbadis, et al., 1999; Chervin & Aldrich, 1999; 
Chervin, Aldrich, & Pickett, 1997; Johns, 1991; Johns, 1994; Punjabi, et al., 2003; 
Sangal, Mitler, & Sangal, 1999).      
Previous research quantifying daytime sleepiness has been conducted using 
subjective measures or conducted within a clinical population; there is a lack of large-
scale, normative data on daytime sleepiness in samples representative of the general 
population. The purpose of this study was to provide population based data using 
physiologic and objective measurements to quantify the objective level of daytime 
sleepiness. This will not only provide valid and reliable results for the distribution and 
prevalence of the level of daytime sleepiness, but also raise awareness surrounding the 
impending negative public health effects.  
Summary of primary findings 
  The sample for this study included 227 participants, with the majority of the 
sample being white females around 50 years of age. Participants were screened in a 
detailed phone interview and reexamined in a clinical evaluation to detect for any 
medical or psychiatric conditions. A current sleep disorder, a prior sleep disorder 
diagnosis, or sleep complaint were also considered exclusionary conditions. Each 
participant underwent standard nocturnal polysomnography and a standard multiple sleep 
latency test (MSLT) on the subsequent day.     
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 The mean (SD) sleep latency of the sample was 8.8 (4.9) minutes; 26.8% had a 
mean sleep latency <5 minutes, 37.1% had a mean sleep latency between 5-10 minutes, 
and 36.2% had a sleep latency > 10 minutes. Twenty-four individuals had ≥1 SOREMP 
and were significantly sleepier than individuals without SOREMP. A total of 100 
individuals had a previously unidentified sleep disorder. The most common sleep 
disorders were sleep apnea (24.4%), periodic limb movements in sleep (16.4%), and 
narcolepsy (2.3%).  
Individuals with shorter sleep latencies, compared to those with longer latencies 
reported higher levels of subjective sleepiness, had better sleep efficiency percentages, 
and longer sleep times. The Epworth Sleepiness Scale, sleep efficiency percentage, total 
sleep time, and the presence of a sleep disorder were positively associated with a mean 
sleep latency of <5 minutes. Sleep efficiency percentage, S4% of TST, and REM% of 
TST were positively associated with ≥1 SOREMP; S1% of TST and S2% of TST were 
negatively associated with ≥1 SOREMP 
SOREMP 
  The prevalence of SOREMPs in this study sample are comparable with the 
findings of another recent study conducted by Singh, Drake, and Roth (2006), assessing 
the prevalence of SOREMPs in a population-based sample. The population-based study 
conducted in southeastern Michigan studied 333 participants and found ≥2 SOREMP at a 
prevalence of 3.9%. In the current study sample, 2.8% had ≥2 SOREMP. The percentage 
of individuals with 0, 1, 2, and 3 SOREMPs in the Singh et al. study are distributed as 
follows: 86.7%, 9.4%, 2.5%, and 1.1% (two individuals with >3 SOREMPs). In the 
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current study, the distribution of 0, 1, 2, and 3 SOREMPs are as follows: 88.7%, 8.5%, 
0.9%, and 1.9%. The two studies are also similar in that an inverse relationship was 
found between SOREMP and mean sleep latencies; a higher prevalence of SOREMPs 
were found in the individuals with shorter mean sleep latencies. Singh et al. (2006) found 
the only sleep-related variable significantly associated with SOREMPs was excessive 
daytime sleepiness (low mean sleep latency), objectively measured by the MSLT. Our 
study also found a significant relationship between SOREMP and sleep latency time. 
 The occurrence of SOREMP was described by Vogel in 1960 and later associated 
with narcolepsy by Rechtschaffen et al in 1963 (Rechtschaffen & Wolpert, 1963; Vogel, 
1960;). REM onset was found to be exclusively associated with narcolepsy in the 1960’s, 
and the first definition of this disorder included irregularities of REM (Oswald, 1976). 
Subsequent studies confirmed that the appearance of ≥2 SOREMPs were considered 
pathognomonic to narcolepsy and considered “highly diagnostic.” These studies were 
challenged in the 1980s by findings of SOREMPs in patients with periodic limb 
movements, sleep apnea, and healthy young adults. (Mignot et al., 2006; Singh et al., 
2006). Causes of SOREMPs have been identified, including REM sleep deprivation, 
alcoholism, drug withdrawal, major depression, and sleep-wake schedule abnormalities, 
and must be controlled for in studies examining factors contributing to SOREMP (Singh 
et al., 2006). 
 Very few studies have been conducted outside of a clinical population to assess 
the prevalence of SOREMP in healthy controls. The high prevalence of SOREMP found 
in our population-based sample corresponds with other findings from studies in a healthy 
sample. A study conducted in 1998 by Geisler et al., found ≥1 SOREMP in 11% (n=100) 
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of a healthy sample, and ≥2 SOREMP in 3% of the sample. The prevalence of ≥1 
SOREMP in our study was 10.9%, and the prevalence of ≥2 SOREMP was 2.7%. An 
additional study conducted in by Mignot et al. (2006), also found a high frequency of 
SOREMP during the MSLT in a random sample of healthy adults. Consistant with our 
study, multiple studies have found subjective sleepiness and total sleep time are not 
significantly associated with SOREMP, and a significant association with sleep latency 
time (Bishop, Rosenthal, Helmus, Roehrs, & Roth, 1996; Mignot et al., 2006; Singh et 
al., 2006). Collectively with our study, initial studies conducted within healthy samples 
suggest SOREMPs are not only present in sleeping disorders and point towards an 
alleged higher prevalence in the general population (Mignot et al., 2006).  
Sleep disorders 
The presence of a significant percentage  of sleep disorders within our study 
sample validate prior suggestions that such disorders remain unrecognized, undiagnosed, 
and untreated (Roth, 1995; “Wake up America,” 1993). Lack of health care provider 
education of sleep disorders is stated as one reason for this deficit. In a four-year medical 
school program curriculum in the United States, an average of 2 hours of content is 
provided in sleep medicine. Didactic teaching (of more than 4 hours) on sleep is offered 
in less than 5% of medical schools, and of this 5%, most are offered as elective courses in 
the 4
th
 year. A mere 8% of medical students are trained in sleep lab procedures, and only 
11% have take part in the clinical evaluation of patients with sleep disorders. This 
suggests the level of knowledge and education within the health care field is lacking, 
despite the substantiation of sleep as an intricate part of healthiness and wellbeing 
(Rosen, Rosekind, Rosevear, Cole, & Dement, 1993).  
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Obstructive Sleep Apnea 
The most prevalent sleep disorder detected through the nocturnal PSG in this 
study was obstructive sleep apnea (OSA). OSA was detected in 28.2% of males and 
23.7% of females (24.9% of the total sample). The detected prevalence of OSA in 
females of this study was much higher than estimates of 9% in the general U.S. 
population, but the detected prevalence of OSA in males of this study was comparable to 
estimates of 24% in the general U.S. population (Gottlieb et al., 2010). 
Health care providers often fail to recognize, or see importance in, major risk 
factors and symptoms associated with OSA (Rahaghi & Basner, 1999). It is estimated 
that 93% of women and 82% of men with moderate to severe sleep apnea may go 
undiagnosed (Young, Evans, Finn, & Palta, 1997). Obstructive sleep apnea is just 
beginning to gain recognition as one of the most under-diagnosed chronic diseases. The 
resultant morbidity and mortality from OSA exceed that of any other sleep disorder. 
Negative health outcomes include daytime sleepiness, as well as coronary artery disease, 
hypertension, myocardial infarction, cardiac arrhythmias, diabetes, and increased risk of 
congestive heart failure (Levendowski et al., 2008).        
Periodic Limb Movements in sleep 
The second most detected sleep disorder was periodic limb movements in sleep 
(PLMS). The detected prevalence of PLMS within our study sample was 16.4%. PLMS is 
detected in standard nocturnal sleep studies at a prevalence rate of 25% in patients 
without RLS, but are typically read as incidental findings associated with alternate sleep 
disorders. PLMS is present in 90% of patients with restless legs syndrome (RLS) (Trotti 
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et al., 2009; Walters & Rye, 2009). PLMS occurring in individuals with insomnia and/or 
hypersomnia that is not explained by another factor is considered PLMD.  The largest 
epidemiological study conducted to date assessing PLMD and sleep complaints, found a 
prevalence of 3.9% in a study sample of 18,980 participants (Ohayon & Roth, 2002).      
PLMS can result in fragmented sleep, insomnia, and excessive daytime 
sleepiness. In turn, daily functioning and quality of life are impacted as well (Ohayon & 
Roth, 2002). PLMS is associated with a physiologic arousal response measured by the 
electroencephalographic (EEG), called a microarousal. Heart rate changes have also been 
observed in 99% of individuals with PLMS, and consistently occur prior to the 
movement. This suggests the autonomic activation is not a cardiac response to motor 
activation, but instead takes part in the arousal process (Gosselin et al., 2003). Multiple 
studies have shown significant relationships between PLMS and hypertension, 
cardiovascular disease, and cerebrovascular disease; however, a direction of causality has 
not yet been established (Trotti et al., 2009; Walters & Rye, 2009).  
Narcolepsy 
The third most detected sleep disorder detected in this study was narcolepsy, 
prevalent in 2.3% of our study sample. This prevalence is much higher than the 
population-based estimates of .02-.07% (Hublin, Partinen, Kaprio, Koskenvuo, & 
Guilleminault, 1994; Longstreth, Koepsell, Ton, Hendrickson, & Van Belle, 2007).  
As with sleep apnea, narcolepsy is also under-recognized and under-diagnosed. 
The disorder has a variety of symptoms and subtle onset, but the public as well as health 
professionals are unfamiliar with the disorder. Major symptoms of narcolepsy are not 
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exclusive to the disease, thus many patients are unaware they are facing the onset of a 
marked neurological disorder and do not seek medical advice. The considerations of 
symptoms alone can cause great difficulty in establishing an accurate diagnosis of the 
disorder due to the lack of specificity (Narcolepsy Fact Sheet, 2010). Without early 
detection and treatment, narcolepsy can significantly impact quality of life. A major 
effect of narcolepsy is excessive daytime sleepiness; driving impairments are also very 
prevalent, along with negative occupational effects and increased risk for crashes and 
injury (Broughton et al., 1981). Narcolepsy can also impair education, the establishment 
of relationships, family life, and social activities (Daniels, King, Smith, & Shneerson, 
2001).        
Insomnia 
 Insomnia is the most common sleep disorder in the United States with symptoms 
prevalent is 33-50% of the general adult population (Roth et al., 2007; Schutte-Rodin et 
al., 2008). Insomnia is defined as the subjective notion of difficulty falling asleep, 
maintaining sleep, consolidation, or complaints of nonrestorative sleep disrupting daily 
functioning (Schutte-Rodin et al., 2008). The focus of this study was the quantification of 
daytime sleepiness through use of objective measures. The appropriate subjective 
measures for detecting insomnia were not employed in the current study, thus the 
numbers obtained from the study are not representative of the actual prevalence rate of 
the disorder. 
Epworth Sleepiness Scale  
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The significant association of the ESS with the mean sleep latency as measured 
by the MSLT in this study is comparable to previously published studies. A study 
examining data from the Wisconsin Sleep Cohort Study (a representative sample from the 
general population) determined scores on the ESS were associated with MSLT mean 
sleep latency. A moderate association was found; individuals with an ESS scores of 6-11 
were at a 30% increased risk for sleep onset and individuals with an ESS score >12 were 
at a 69% increased risk for sleep onset during the MSLT. Multiple other comparisons of 
results from the ESS and MSLT have found similar findings (Johns, 1994; Johns, 1991; 
Punjabi et al., 2003). 
 The data presented here diverge from a number of previous reports that have 
found weak or no significant association between the ESS and the MSLT (Benbadis et 
al., 1999; Chervin, et al., 1997; Chervin & Aldrich, 1999, Sangal et al., 1999). Reasons 
for inconsistency among studies could be due to the differences in study populations and 
sample size (Sangal et al., 1999). The controversial nature of this finding suggest that 
future research is needed within representative population-based samples to determine the 
associations between self-report measures of sleepiness and objective measures of 
daytime sleepiness.   
Limitations 
Limitations of this study reflect aspects of the study design. The participants of 
the study represented a population-based sample. However, the population was 
oversampled for fatigue; therefore, the number of fatigued individuals in the sample must 
be considered. In general, participants were overweight or obese. Obesity has been 
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distinguished to have an effect on sleep, thus the results cannot be generalized to 
individuals with a normal BMI (Knutson, 2010; Van Cauter et al., 2008). In addition, the 
majority of the study sample was older women. Menopausal status has a notable impact 
on sleep, and this report did not include data pertaining to menopausal status (Young, 
Finn, Austin, & Peterson, 2003). We also did not have data on whether our participants 
were working night or rotating shifts. Night shift workers are at higher risk for sleepiness 
than day shift workers (Akerstedt, 1988; Akerstedt, 1995; Akerstedt, 2003). As with other 
limitations above, further studies must be conducted to explore these differences in order 
to expand our understanding of daytime sleepiness. 
Future directions  
The cross-sectional design of this study does not allow for the establishment of 
causality. The substantial public health burden of daytime sleepiness requires 
consideration; however, much of the current data has come from measures within a 
clinical population or by using subjective assessments (Breslau, Roth, Rosenthal, & 
Andreski, 1997; Punjabi, et al., 2003). Epidemiologic data substantiating objective levels 
of daytime sleepiness within the general population are insufficient and further studies 
with a larger, more representative sample size is necessary. Population-based studies 
using objective measures are essential in provide prevalence data and risk factors 
associated with daytime sleepiness, as this information is important for the future of sleep 
disorders research. The imminent role for of public health within this area of research is 
not only in the future research, but also in education, the promotion of healthy sleep 
habits, and prevention.
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